学术论文

      胰高血糖素样肽-1受体激动剂在糖尿病性勃起功能障碍患者中的潜在治疗作用

      The potential therapeutic effects of glucagon like peptide-1 receptor agonists in patients with diabetes mellitus induced erectile dysfunction

      摘要:
      糖尿病性勃起功能障碍(DIED)是2型糖尿病的一种常见并发症,严重影响男性2型糖尿病患者的身心健康.DIED的发生涉及血管组织、神经、内分泌等多种病理生理改变,传统治疗勃起功能障碍的方法对于DIED效果却不甚理想.胰高血糖素样肽(GLP)-1受体激动剂是一种新型降糖药物,代表药物有艾塞那肽和利拉鲁肽,二者的疗效已在临床得到证实.近年研究发现GLP-1受体激动剂可以通过多种机制改善内皮细胞功能、神经病变和性激素的分泌,减轻体质量和胰岛素抵抗,因此,此类药物可能成为DIED患者的新选择.
      Abstract:
      Diabetic mellitus induced erectile dysfunction (DIED) is a common complication of type 2 diabetes mellitus (T2DM), which seriously affects the physical and mental health of male T2DM patients. The occurrence of DIED involves a variety of pathophysiological changes such as vascular tissue, nerve, endocrine and so on. But the traditional treatment of erectile dysfunction is not ideal for DIED. Glucagon like peptide (GLP)- 1 receptor agonist has been widely used as a new drug for the treatment of diabetes, and the representative drugs are exenatide and liraglutide. Existing research shows that it can improve endothelial cell function, neuropathy and sex hormone secretion, reduce body weight and insulin resistance. Therefore, these drugs may be a new choice for patients with DIED.
      Author: Dong Fengjiao Wang Lihong Che Hui Liang Meihua Fu Xuelian
      作者单位: 150001,哈尔滨医科大学附属第二医院内分泌代谢病二病房
      刊 名: 中国医师进修杂志 ISTIC
      年,卷(期): 2017, 40(3)
      在线出版日期: 2017年3月31日
      基金项目: 黑龙江省应用科技研究与开发计划项目,Project of Applied Science and Technology Research and Development in Heilongjiang Province